123 related articles for article (PubMed ID: 8826889)
1. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma.
Abrahamson GM; Bird JM; Newland AC; Gaminara E; Giles C; Joyner M; Kelsey SM; Lewis D; McCarthy DM; Roques AW; Tew CJ; Treacy M; van de Pette J; Samson D
Br J Haematol; 1996 Sep; 94(4):659-64. PubMed ID: 8826889
[TBL] [Abstract][Full Text] [Related]
2. Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma.
Kars A; Celik I; Kansu E; Tekuzman G; Ozişik Y; Güler N; Barişta I; Güllü I; Yalçin S; Altundağ K; Zengin N; Türker A; Hayran M; Baltali E; Firat D
Eur J Haematol; 1997 Aug; 59(2):100-4. PubMed ID: 9293857
[TBL] [Abstract][Full Text] [Related]
3. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
Salmon SE; Crowley JJ; Balcerzak SP; Roach RW; Taylor SA; Rivkin SE; Samlowski W
J Clin Oncol; 1998 Mar; 16(3):890-6. PubMed ID: 9508170
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
[TBL] [Abstract][Full Text] [Related]
5. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
Bladé J; San Miguel JF; Escudero ML; Fontanillas M; Besalduch J; Gardella S; Arias J; García-Conde J; Carnero M; Marti JM; Rozman C; Estapé J; Montserrat E
Leukemia; 1998 Jul; 12(7):1144-8. PubMed ID: 9665202
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma.
Young RI; Ranson M; Chang J; Lord B; Testa N; Scarffe JH
Eur J Cancer; 1997 Feb; 33(2):307-11. PubMed ID: 9135507
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
9. VAD-based regimens as primary treatment for multiple myeloma.
Alexanian R; Barlogie B; Tucker S
Am J Hematol; 1990 Feb; 33(2):86-9. PubMed ID: 2301376
[TBL] [Abstract][Full Text] [Related]
10. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
11. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
Cook G; Clark RE; Morris TC; Robertson M; Lucie NP; Anderson S; Paul J; Franklin IM
Br J Haematol; 2004 Sep; 126(6):792-8. PubMed ID: 15352982
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.
Ludwig H; Cohen AM; Polliack A; Huber H; Nachbaur D; Senn HJ; Morant R; Eckhardt S; Günczler P; Seewann HL
Ann Oncol; 1995 May; 6(5):467-76. PubMed ID: 7669712
[TBL] [Abstract][Full Text] [Related]
13. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
14. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
15. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.
Phillips JK; Sherlaw-Johnson C; Pearce R; Davies JM; Reilly JT; Newland AC; Cawley JC
Leuk Lymphoma; 1995 May; 17(5-6):465-72. PubMed ID: 7549839
[TBL] [Abstract][Full Text] [Related]
16. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.
Mandelli F; Avvisati G; Amadori S; Boccadoro M; Gernone A; Lauta VM; Marmont F; Petrucci MT; Tribalto M; Vegna ML
N Engl J Med; 1990 May; 322(20):1430-4. PubMed ID: 2184356
[TBL] [Abstract][Full Text] [Related]
17. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
Friedenberg WR; Rue M; Blood EA; Dalton WS; Shustik C; Larson RA; Sonneveld P; Greipp PR
Cancer; 2006 Feb; 106(4):830-8. PubMed ID: 16419071
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W" Czech Myeloma Group].
Adam Z; Krejcí M; Bacovský J; Hejlová N; Kuca B; Svojgrová M; Franková H; Gumulec J; Janca J; Veprek K; Januska B; Lehanka F; Rezek Z; Praskac P; Cahová S; Vránová M; Papajík T; Králová E; Novotná J; Scudla V; Koza V; Drbal J; Faber E; Mareschová I; Hájek R
Vnitr Lek; 1998 Jul; 44(7):400-8. PubMed ID: 9748876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
